Login Register Cart 0
Generic placeholder image

Current Respiratory Medicine Reviews

Editor-in-Chief

ISSN (Print): 1573-398X
ISSN (Online): 1875-6387

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Diabetes and Lung Cancer: A Sweet and Sour Relationship

Author(s): Andreas Paraskevas, Elena Bellou, Elli Keramida, Irma Bracka, Christina Gkriniouk, Spyros Mazarakis, Ioannis Karampinis, Panagiotis Demertzis and Georgia Hardavella*

Volume 18, Issue 4, 2022

Published on: 16 November, 2021

Page: [241 - 246] Pages: 6

DOI: 10.2174/1573398X17666210917100152

Price: $65

Abstract

Introduction: Diabetes mellitus and lung cancer are two highly prevalent diseases on a global scale. The association between these two diseases has been the subject of study of many cohorts in the past, some of which presenting inconclusive results.

Aim: To present existing evidence regarding the association of diabetes with lung cancer risk and survival as well as the impact of metformin and insulin on lung cancer.

Methods: A narrative review of all the relevant published literature known to the authors was conducted. The references were identified by searching the Pubmed online database using the keywords such as diabetes and lung cancer risk, diabetes and lung cancer survival rates, metformin and lung cancer, insulin and lung cancer.

Results: Although previous epidemiologic studies have failed to report any significant causal effect of diabetes on lung cancer risk, recent evidence from 2 large scale meta-analyses of observational studies and other studies showed a statistically significant correlation between nonsmoker diabetics and lung cancer risk (RR, 1.11; 95% CI, 1.02-1.20; I2 = 46.1% and RR, 1.14; 95% CI, 1.09-1.20; I2 = 0%). Recent evidence has shown that metformin is related to a lower risk of lung cancer incidence among never-smokers diabetic patients (HR, 0.57;95% CI, 0.33-0.99) and improved overall survival rates (HR=0.77, 95%CI=0.66-0.9, P=0.001) regardless of the histological type of lung cancer. On the other hand, a recently published large population-based retrospective cohort study has concluded that human insulin is associated with an increased risk of lung cancer (HR 1.545, 95% CI: 1.478-1.614). Interestingly, metformin has been reported to have an anti-resistant effect on lung cancer patients who are on Epidermal Growth Factor Receptor- Tyrosine Kinase Inhibitors, offering some protection against resistance to therapy.

Conclusion: Published evidence shows that diabetes mellitus is associated with an increased risk of lung cancer and worse survival rates. Metformin plays a protective role in lung cancer pathogenesis and is also associated with prolonged progression-free survival in lung cancer patients with diabetes. There is a significant association between human insulin use and lung cancer risk. More randomized controlled studies are required to establish the positive association of diabetes and anti-diabetic drugs with lung cancer, taking into further consideration gender and lung cancer pathology as well as possible confounders such as smoking habits that can influence the results of these studies.

Keywords: Diabetes, lung cancer, metformin, insulin, risk, causal effect.

« Previous Next »
[1]
American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care, 2009, 32(Suppl. 1), S62-S67.
[http://dx.doi.org/10.2337/dc09-S062] [PMID: 19118289]
[2]
Khan, M.A.B.; Hashim, M.J.; King, J.K.; Govender, R.D.; Mustafa, H.; Al Kaabi, J. Epidemiology of Type 2 diabetes - Global burden of disease and forecasted trends. J. Epidemiol. Glob. Health, 2020, 10(1), 107-111.
[http://dx.doi.org/10.2991/jegh.k.191028.001] [PMID: 32175717]
[3]
Malhotra, J.; Malvezzi, M.; Negri, E.; La Vecchia, C.; Boffetta, P. Risk factors for lung cancer worldwide. Eur. Respir. J., 2016, 48(3), 889-902.
[http://dx.doi.org/10.1183/13993003.00359-2016] [PMID: 27174888]
[4]
Carreras-Torres, R.; Johansson, M.; Haycock, P.C.; Wade, K.H.; Relton, C.L.; Martin, R.M.; Davey Smith, G.; Albanes, D.; Aldrich, M.C.; Andrew, A.; Arnold, S.M.; Bickeböller, H.; Bojesen, S.E.; Brunnström, H.; Manjer, J.; Brüske, I.; Caporaso, N.E.; Chen, C.; Christiani, D.C.; Christian, W.J.; Doherty, J.A.; Duell, E.J.; Field, J.K.; Davies, M.P.A.; Marcus, M.W.; Goodman, G.E.; Grankvist, K.; Haugen, A.; Hong, Y.C.; Kiemeney, L.A.; van der Heijden, E.H.F.M.; Kraft, P.; Johansson, M.B.; Lam, S.; Landi, M.T.; Lazarus, P.; Le Marchand, L.; Liu, G.; Melander, O.; Park, S.L.; Rennert, G.; Risch, A.; Haura, E.B.; Scelo, G.; Zaridze, D.; Mukeriya, A.; Savić, M.; Lissowska, J.; Swiatkowska, B.; Janout, V.; Holcatova, I.; Mates, D.; Schabath, M.B.; Shen, H.; Tardon, A.; Teare, M.D.; Woll, P.; Tsao, M.S.; Wu, X.; Yuan, J.M.; Hung, R.J.; Amos, C.I.; McKay, J.; Brennan, P. Obesity, metabolic factors and risk of different histological types of lung cancer: A Mendelian randomization study. PLoS One, 2017, 12(6), e0177875.
[http://dx.doi.org/10.1371/journal.pone.0177875] [PMID: 28594918]
[5]
Zhu, L.; Cao, H.; Zhang, T.; Shen, H.; Dong, W.; Wang, L.; Du, J. The effect of diabetes mellitus on lung cancer prognosis: a prisma-compliant meta-analysis of cohort studies. Medicine (Baltimore), 2016, 95(17), e3528.
[http://dx.doi.org/10.1097/MD.0000000000003528] [PMID: 27124062]
[6]
Hall, G.C.; Roberts, C.M.; Boulis, M.; Mo, J.; MacRae, K.D. Diabetes and the risk of lung cancer. Diabetes Care, 2005, 28(3), 590-594.
[http://dx.doi.org/10.2337/diacare.28.3.590] [PMID: 15735193]
[7]
Steenland, K.; Nowlin, S.; Palu, S. Cancer incidence in the National Health and Nutrition Survey I. Follow-up data: diabetes, cholesterol, pulse and physical activity. Cancer Epidemiol. Biomarkers Prev., 1995, 4(8), 807-811.
[PMID: 8634649]
[8]
Chowdhury, T.A. Diabetes and cancer. QJM, 2010, 103(12), 905-915.
[http://dx.doi.org/10.1093/qjmed/hcq149] [PMID: 20739356]
[9]
Park, H.J.; Joh, H.K.; Choi, S.; Park, S.M. Type 2 diabetes mellitus does not increase the risk of lung cancer among never-smokers: a nationwide cohort study. Transl. Lung Cancer Res., 2019, 8(6), 1073-1077.
[http://dx.doi.org/10.21037/tlcr.2019.11.01] [PMID: 32010584]
[10]
Yang, W.S.; Yang, Y.; Yang, G.; Chow, W.H.; Li, H.L.; Gao, Y.T.; Ji, B.T.; Rothman, N.; Zheng, W.; Shu, X.O.; Xiang, Y.B. Pre-existing type 2 diabetes and risk of lung cancer: a report from two prospective cohort studies of 133 024 Chinese adults in urban Shanghai. BMJ Open, 2014, 4(7), e004875.
[http://dx.doi.org/10.1136/bmjopen-2014-004875] [PMID: 24993754]
[11]
Lee, J.Y.; Jeon, I.; Lee, J.M.; Yoon, J.M.; Park, S.M. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. Eur. J. Cancer, 2013, 49(10), 2411-2423.
[http://dx.doi.org/10.1016/j.ejca.2013.02.025] [PMID: 23562551]
[12]
Yi, Z.H.; Luther, Y.; Xiong, G.H.; Ni, Y.L.; Yun, F.; Chen, J.; Yang, Z.; Zhang, Q.; Kuang, Y.M.; Zhu, Y.C. Association between diabetes mellitus and lung cancer: Meta-analysis. Eur. J. Clin. Invest., 2020, 50(10), e13332.
[http://dx.doi.org/10.1111/eci.13332] [PMID: 32589285]
[13]
Hatlen, P.; Grønberg, B.H.; Langhammer, A.; Carlsen, S.M.; Amundsen, T. Prolonged survival in patients with lung cancer with diabetes mellitus. J. Thorac. Oncol., 2011, 6(11), 1810-1817.
[http://dx.doi.org/10.1097/JTO.0b013e31822a75be] [PMID: 21964531]
[14]
Wang, N.F.; Tang, H.M.; Liu, F.L.; Hong, Q.Y. Prolonged progression-free survival and overall survival are associated with diabetes mellitus but inversely associated with levels of blood glucose in patients with lung cancer. Chin. Med. J. (Engl.), 2020, 133(7), 786-791.
[http://dx.doi.org/10.1097/CM9.0000000000000739] [PMID: 32195672]
[15]
Deng, H.Y.; Zheng, X.; Zha, P.; Peng, L.; Huang, K.L.; Qiu, X.M. Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis. Thorac. Cancer, 2019, 10(3), 571-578.
[http://dx.doi.org/10.1111/1759-7714.12985] [PMID: 30706684]
[16]
Holman, R. Metformin as first choice in oral diabetes treatment: the UKPDS experience. Journ. Annu. Diabetol. Hotel Dieu, 2007, 13-20.
[PMID: 18613325]
[17]
Ekman, S.; Wynes, M.W.; Hirsch, F.R. The mTOR pathway in lung cancer and implications for therapy and biomarker analysis. J. Thorac. Oncol., 2012, 7(6), 947-953.
[http://dx.doi.org/10.1097/JTO.0b013e31825581bd] [PMID: 22588151]
[18]
Saraei, P.; Asadi, I.; Kakar, M.A.; Moradi-Kor, N. The beneficial effects of metformin on cancer prevention and therapy: a comprehensive review of recent advances. Cancer Manag. Res., 2019, 11, 3295-3313.
[http://dx.doi.org/10.2147/CMAR.S200059] [PMID: 31114366]
[19]
Aljofan, M.; Riethmacher, D. Anticancer activity of metformin: a systematic review of the literature. Future Sci. OA, 2019, 5(8), FSO410.
[http://dx.doi.org/10.2144/fsoa-2019-0053] [PMID: 31534778]
[20]
Cheng, H.; Shcherba, M.; Pendurti, G.; Liang, Y.; Piperdi, B.; Perez-Soler, R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment. Lung Cancer Manag., 2014, 3(1), 67-75.
[http://dx.doi.org/10.2217/lmt.13.72] [PMID: 25342981]
[21]
Kasznicki, J.; Sliwinska, A.; Drzewoski, J. Metformin in cancer prevention and therapy. Ann. Transl. Med., 2014, 2(6), 57.
[PMID: 25333032]
[22]
Sakoda, L.C.; Ferrara, A.; Achacoso, N.S.; Peng, T.; Ehrlich, S.F.; Quesenberry, C.P., Jr; Habel, L.A. Metformin use and lung cancer risk in patients with diabetes. Cancer Prev. Res. (Phila.), 2015, 8(2), 174-179.
[http://dx.doi.org/10.1158/1940-6207.CAPR-14-0291] [PMID: 25644512]
[23]
Suissa, S.; Azoulay, L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care, 2012, 35(12), 2665-2673.
[http://dx.doi.org/10.2337/dc12-0788] [PMID: 23173135]
[24]
Gandini, S.; Puntoni, M.; Heckman-Stoddard, B.M.; Dunn, B.K.; Ford, L.; DeCensi, A.; Szabo, E. Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders. Cancer Prev. Res. (Phila.), 2014, 7(9), 867-885.
[http://dx.doi.org/10.1158/1940-6207.CAPR-13-0424] [PMID: 24985407]
[25]
Cao, X.; Wen, Z.S.; Wang, X.D.; Li, Y.; Liu, K.Y.; Wang, X. The clinical effect of metformin on the survival of lung cancer patients with diabetes: A comprehensive systematic review and meta-analysi of retrospective studies. J. Cancer, 2017, 8(13), 2532-2541.
[http://dx.doi.org/10.7150/jca.19750] [PMID: 28900491]
[26]
Wang, H.; Yang, X.; Sun, Y.; Li, Y.; Dong, Y.; Shan, D.; Yu, Z. Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer. Transl. Cancer Res., 2020, 9(1)
[http://dx.doi.org/10.21037/tcr.2019.11.09]
[27]
Oscar Arrieta, MD Effect of metformin plus tyrosine kinase inhibiors alone in patients with epidermal growth factor receptor- mutated lung adenocarcinoma. a phase 2 randomized clinical trial. JAMA Oncol., 2019, 5(11), e192553.
[http://dx.doi.org/10.1001/jamaoncol.2019.2553] [PMID: 31486833]
[28]
“Clinical utility of insulin and insulin analogs.” Islets, 2013, vol. 5(2), 67-78.
[http://dx.doi.org/10.4161/isl.24590]
[29]
Frisch, C.M.; Zimmermann, K.; Zilleßen, P.; Pfeifer, A.; Racké, K.; Mayer, P. Non-small cell lung cancer cell survival crucially depends on functional insulin receptors. Endocr. Relat. Cancer, 2015, 22(4), 609-621.
[http://dx.doi.org/10.1530/ERC-14-0581] [PMID: 26113601]
[30]
Belfiore, A.; Malaguarnera, R. Insulin receptor and cancer. Endocr. Relat. Cancer, 2011, 18(4), R125-R147.
[http://dx.doi.org/10.1530/ERC-11-0074] [PMID: 21606157]
[31]
Weroha, SJ; Haluska, P The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am., 2012, 41(2), 335-350, vi. PMCID: PMC3614012.
[http://dx.doi.org/10.1016/j.ecl.2012.04.014] [PMID: 22682634]
[32]
Kim, J.S.; Kim, E.S.; Liu, D.; Lee, J.J.; Solis, L.; Behrens, C.; Lippman, S.M.; Hong, W.K.; Wistuba, I.I.; Lee, H.Y. Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer. Cancer, 2012, 118(9), 2454-2465.
[http://dx.doi.org/10.1002/cncr.26492] [PMID: 21952750]
[33]
Yamamoto, T.; Oshima, T.; Yoshihara, K.; Nishi, T.; Arai, H.; Inui, K.; Kaneko, T.; Nozawa, A.; Adachi, H.; Rino, Y.; Masuda, M.; Imada, T. Clinical significance of immunohistochemical expression of insulin-like growth factor-1 receptor and matrix metalloproteinase-7 in resected non-small cell lung cancer. Exp. Ther. Med., 2012, 3(5), 797-802.
[http://dx.doi.org/10.3892/etm.2012.493] [PMID: 22969971]
[34]
Stocks, T.; Borena, W.; Strohmaier, S.; Bjørge, T.; Manjer, J.; Engeland, A.; Johansen, D.; Selmer, R.; Hallmans, G.; Rapp, K.; Concin, H.; Jonsson, H.; Ulmer, H.; Stattin, P. Cohort Profile: The Metabolic syndrome and Cancer project (Me-Can). Int. J. Epidemiol., 2010, 39(3), 660-667.
[http://dx.doi.org/10.1093/ije/dyp186] [PMID: 19380371]
[35]
Kuhajda, FP AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int J Obes (Lond), 2008, 32(Suppl 4(Suppl 1)), S36-S41. PMCID: PMC7104469
[http://dx.doi.org/10.1038/ijo.2008.121] [PMID: 18719597]
[36]
Hemkens, L.G.; Grouven, U.; Bender, R.; Günster, C.; Gutschmidt, S.; Selke, G.W.; Sawicki, P.T. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia, 2009, 52(9), 1732-1744.
[http://dx.doi.org/10.1007/s00125-009-1418-4] [PMID: 19565214]
[37]
Fagot, J.P.; Blotière, P.O.; Ricordeau, P.; Weill, A.; Alla, F.; Allemand, H. Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases. Diabetes Care, 2013, 36(2), 294-301.
[http://dx.doi.org/10.2337/dc12-0506] [PMID: 22966091]
[38]
Warburg, O. On the origin of cancer cells. Science, 1956, 123(3191), 309-314.
[http://dx.doi.org/10.1126/science.123.3191.309] [PMID: 13298683]
[39]
Yang, XL; Ma, RC; So, WY; Kong, AP; Xu, G; Chan, JC Addressing different biases in analysing drug use on cancer risk in diabetes in non-clinical trial settings-what, why and how? Diabetes ObesMetab, 2012, 14(7), 579-585. Epub 2012 Jan 17.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01551.x.] [PMID: 22171706]
[40]
Yang, Xi-Lin; Chan, Juliana Cn Diabetes, insulin and cancer risk. World journal of diabetes, 2012, vol. 3(4), 60-64.
[http://dx.doi.org/10.4239/wjd.v3.i4.60]
[41]
Chin-Hsiao, Tseng Human insulin therapy is associated with an increased risk of lung cancer: A population based retrospective cohort study. Front. Endocrinol., 2019, 11.
[http://dx.doi.org/10.3389/fendo.2019.00443]

Rights & Permissions Print Cite
Article Metrics
1
© 2024 Bentham Science Publishers | Privacy Policy